Navigation Links
Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
Date:12/31/2007

PITTSBURGH, Dec. 31 /PRNewswire-FirstCall/ Mylan Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Balsalazide Disodium Capsules, 750 mg.

Balsalazide Disodium Capsules are the generic version of Salix Pharmaceuticals' Colazal(R) Capsules, which had U.S. sales of approximately $130.9 million for the 12 months ending Sept. 30, 2007.

This product will be shipped immediately.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.


'/>"/>
SOURCE Mylan Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... N.Y. , May 22, 2013  Empire ... license for a patent pending novel genomic biomarker ... molecular diagnostic test that could help in diagnosing ... prostate cancer.  Neuroendocrine prostate cancer ... (PCA) that can arise de novo, but more ...
(Date:5/22/2013)... and NEW ORLEANS , May ... the field of regenerative medicine, presented new data generated ... Analysis Group (a leading health economics consultancy) demonstrating the ... ulcers (DFU) and venous leg ulcers (VLU) place upon ... of this research, which reveal annual costs of up ...
(Date:5/22/2013)... , May 22, 2013  Cleveland BioLabs, Inc. (NASDAQ: CBLI) ... the Second Annual Marcum LLP Microcap Conference, May 30, in ... Neil Lyons , CPA, Chief Financial Officer ... programs on May 30 at 1:30 p.m. Eastern Time.  A ... available on the Investors page of the Cleveland BioLabs website ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Mold remediation could ... said that there is a way to cut down the ... on its latest post the details of a method ... money. , Mold could be prevented, My Cleaning Products said. ... company stated that a mold remediation must then be promptly ...
Breaking Biology Technology:Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2How to Kill Mold While Saving Thousands of Dollars on Mold Remediation Projects Explained by My Cleaning Products 2
... BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced ... will present a,company update at the BioCentury NewsMakers ... on Thursday, September 6, 2007 at 10:30 a.m.,ET. ... webcast of the presentation,via the investor section of ...
... Thursday, September 6, 2007, SAN DIEGO, Aug. ... announced today that Neurocrine Biosciences will,present at the ... presentation takes place Thursday, September 6, 2007 at ... (PT). The presentation will be,simultaneously webcast and may ...
... Pressure,BioSciences, Inc. (Nasdaq: PBIO ) ... its first patent by the Canadian Intellectual ... (Number,2,259,318), this issuance extends the coverage of ... issued in the United States,Japan, Germany, Italy, ...
Cached Biology Technology:Pressure BioSciences, Inc. Issued First Patent in Canada 2Pressure BioSciences, Inc. Issued First Patent in Canada 3
(Date:5/21/2013)... long time that some creatures evolve more quickly than ... But it may be that height plays a role, ... U. S. National Evolutionary Synthesis Center. , In ... journal Nature Communications , Lanfear and colleagues report ... a database of global patterns in plant height for ...
(Date:5/21/2013)... increasingly being considered in the management of natural ... that can help them recognize and respond to ... their lives. , Place-Based Conservation: Perspectives from ... the Pacific Northwest Research Station,s Linda Kruger, can ... The book is published by Springer Verlag and ...
(Date:5/21/2013)... stem cells in the blood often jump into ... cells that can fight off illness. But repeated ... potentially leading to the development of serious blood ... researchers led by biologists at the California Institute ... models, the molecule microRNA-146a (miR-146a) acts as a ...
Breaking Biology News(10 mins):Small but speedy: Short plants live in the evolutionary fast lane 2Keeping stem cells strong 2
... of 154 smokers who had surgery to remove early stage ... of their potentially curative operation, and more than one-third ... patients who started smoking again did so within two months ... University School of Medicine and published in the December issue ...
... of researchers from Arizona State University and Motorola Labs, ... sensors based on carbon nanotubes, microscopically small structures that ... devices detected the presence of heavy metal ions in ... the researchers developed a method for applying peptides to ...
... risky behavior for humans, it's healthy for honeybees: Queen ... produce more disease-resistant colonies than monogamous monarchs. , According ... 7 issue of the Proceedings of the Royal Society ... long perplexed apiculturists, especially since seeking out multiple mates ...
Cached Biology News:Successful lung cancer surgery not enough to break nicotine dependence in many smokers 2Successful lung cancer surgery not enough to break nicotine dependence in many smokers 3Motorola researchers develop selective sensors based on carbon nanotubes 2Queen bee promiscuity boosts hive health 2
Rabbit polyclonal to 3-Ethynylestradiol ( Abpromise for all tested applications). Antigen: Ethynylestradiol conjugated to BSA....
Antibody specific for histone H3 acetylated at any of the five N-terminal lysine residues. Rabbit polyclonal serum. Antigen: Synthetic peptide derived from histone H3 N-terminal region, mulitpliy...
NuCycl DAPI Kit Application: Flow Cytometry Reactivity: Human...
...
Biology Products: